Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies

Shots:

• Dunad to receive $24M up front, equity investment, research funding & is eligible to receive ~$1.3B milestones along with royalties & will also be responsible for program execution up to lead optimization
• Novartis gets an exclusive option to develop and commercialize the product that emerges from the research programs directed against up to 4 drug targets. If Novartis exercises its option, it will lead the development, manufacturing & commercialization globally of small-molecule therapeutic products against the targets
• The agreement will utilize Dunad’s platform to produce novel oral covalent & protein degrading small molecule therapies across multiple target classes

Click here to­ read the full press release/ article | Ref: PR Newswire | Image: BioProcess International